Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11107MR)

This product GTTS-WQ11107MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Hodgkin's disease (HD), Anaplastic large cell lymphoma (ALCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11107MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12412MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NI-0401
GTTS-WQ13210MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ12301MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ10995MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ5520MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ12586MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NV-02
GTTS-WQ5874MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ1174MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW